Substituted heterocyclic ethers and their use in CNS disorders

Abstract

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

1. A compound of Formula I 
       
         
           
           
               
               
           
         
         where: 
         R 1  is hydrogen or alkyl; 
         R 2  is hydrogen, alkyl, cyanoalkyl, haloalkyl, hydroxylalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, N-alkylaminocarbonyl, or N,N-dialkylaminocarbonyl; 
         R 3  is hydrogen or alkyl; 
         Ar 1  is phenyl or pyridinyl and is substituted with 0-3 substituents selected from the group consisting of halo, alkyl, haloalkyl, and cyano; 
         Ar 2  is indolyl, indazolyl, benzimidazolyl, or benzotriazolyl, and is substituted with 0-3 substituents selected from the group consisting of halo, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, cyanoalkyl, hydroxy, alkoxy, haloalkoxy, cyano, amino, alkylamino, dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, (alkyl)piperazinyl, morpholinyl, thiomorpholinyl, and Ar 3 ; and 
         Ar 3  is phenyl substituted with 0-3 substituents selected from the group consisting of halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and cyano; 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
       2. A compound of  claim 1  where R 2  is hydrogen or alkyl and Ar 2  is indolyl, indazolyl, benzimidazolyl, or benzotriazolyl and Ar 2  is substituted with 0-3 substituents selected from the group consisting of halo, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, amino, alkylamino, dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, (alkyl)piperazinyl, morpholinyl, thiomorpholinyl, and Ar 3 . 
     
     
       3. A compound of  claim 1  where R 1  is hydrogen or methyl. 
     
     
       4. A compound of  claim 1  where R 2  is hydrogen and R 3  is hydrogen. 
     
     
       5. A compound of  claim 1  where R 2  is methyl and R 3  is hydrogen. 
     
     
       6. A compound of  claim 1  where Ar 1  is phenyl or monohalophenyl. 
     
     
       7. A compound of  claim 1  where Ar 2  is indazolyl and is substituted with 0-3 substituents selected from the group consisting of halo, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, cyanoalkyl, hydroxy, alkoxy, haloalkoxy, cyano, amino, alkylamino, dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, (alkyl)piperazinyl, morpholinyl, thiomorpholinyl, and Ar 3 . 
     
     
       8. A compound of  claim 1  selected from the group consisting of
 7-Methyl-5-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole; 
 5-Bromo-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole; 
 4-(7-(((4-Phenylpiperidin-4-yl)methoxy)methyl)-1H-indazol-5-yl)benzonitrile; 
 4-(1-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazol-5-yl)benzonitrile; 
 4-(2-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-2H-indazol-5-yl)benzonitrile; 
 5-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole; 
 1,5-Dimethyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole; 
 2,5-Dimethyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-2H-indazole; 
 7-(((4-Phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole; 
 7-(((1-Methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole; 
 1-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole; 
 2-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-2H-indazole; 
 1-Methyl-7-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole; 
 2-Methyl-7-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-2H-indazole; 
 7-(((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)methyl)-5-(trifuoromethyl)-1H-indazole; 
 7-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole; 
 7-(((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)methyl)-1-methyl-5-(trifluoromethyl)-1H-indazole; 
 7-(((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)methyl)-2-methyl-5-(trifluoromethyl)-2H-indazole; 
 7-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-1-methyl-5-(trifluoromethyl)-1H-indazole; 
 (±)-7-(1-((4-Phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole; 
 (±)-7-(1-((1-Methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole; 
 7-(1-((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)ethyl)-5-(trifuoromethyl)-1H-indazole; 
 7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole; 
 7-(1-((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)ethyl)-1-methyl-5-(trifluoromethyl)-1H-indazole; 
 7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-5-(trifluoromethyl)-1H-indazole; 
 7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-2-methyl-5-(trifluoromethyl)-2H-indazole; 
 7-(((4-Phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole; 
 3-Cyclopropyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole; 
 3-Bromo-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole; 
 3-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole; 
 (±)-5-Chloro-7-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-5-Chloro-7-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-5-Chloro-1-methyl-7-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-5-Chloro-2-methyl-7-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-2H-indazole; 
 (±)-3-Methyl-7-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole; 
 (±)-3-Methyl-7-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole; 
 5-Cyclopropyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole; 
 (±)-5-Bromo-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-5-Cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole-5-carbonitrile; 
 (±)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-1H-indazole; 
 (±)-4-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole-5-yl)morpholino; 
 7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-N,N-dimethyl-1H-indazol-5-amine; 
 (±)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methoxy-1H-indazole; 
 (±)-5-Fluoro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 5-Cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-5-Chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-3-methyl-1H-indazole; 
 (±)-5-Chloro-3-cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-3-Bromo-5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-5-Chloro-2-cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-2H-indazole; 
 (±)-3,5-Dichloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (±)-1-(2,2-Difluoroethyl)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-1H-indazole; 
 (±)-2-(2,2-Difluoroethyl)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-2H-indazole; 
 (±)-1-(Cyclopropylmethyl)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-1H-indazole; 
 (±)-2-(Cyclopropylmethyl)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-2H-indazole; 
 (±)-1-Cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-1H-indazole; 
 4-(1-Cyclopropyl-7-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazol-5-yl)benzonitrile; 
 7-(((1-Methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indole; 
 1-Methyl-7-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indole; 
 7-(((1-Methyl-4-(4-fluorophenyl)piperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indole; 
 1-Methyl-7-(((1-methyl-4-(4-fluorophenyl)piperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indole; 
 (±)-7-(1-((1-Methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indole; 
 (±)-1-Methyl-7-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indole; 
 (±)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indole; 
 (±)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-5-(trifluoromethyl)-1H-indole; 
 7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-5-(trifluoromethyl)-1H-indole; 
 4-(((1-Methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)-1H-indole 2,2,2-trifluoroacetate; 
 1-Methyl-4-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)-1H-indole 2,2,2-trifluoroacetate; 
 7-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-1-methyl-5-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole; 
 4-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-2-methyl-6-(trifluoromethyl)-2H-benzo[d][1,2,3]triazole; 
 4-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole; 
 4-(1-(Cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazol-5-yl)benzonitrile; 
 5-Bromo-1-(cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazole; 
 6-Bromo-1-(cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazole; 
 1-(Cyclopropylmethyl)-5-(2,4-dichlorophenyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazole; 
 6-Cyclopropyl-1-(cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazole; 
 1-(Cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole; 
 1-(Cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; and 
 4-(((1-Methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       9. A compound of  claim 1  selected from the group consisting of
 Methyl 2-(5-chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)acetate trifluoroacetic acid salt; 
 2-(5-Chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)acetic acid trifluoroacetic acid salt; 
 2-(5-Chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)-N,N-dimethylacetamide trifluoroacetic acid salt; 
 2-(5-Chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethanol trifluoroacetic acid salt; 
 5-Chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)-2-methoxyethyl)-1H-indazole trifluoroacetic acid salt; 
 5-Chloro-7-(2-fluoro-1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 2-(5-Chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)acetonitrile; 
 6-Chloro-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-benzo[d]imidazol-2(3H)-one trifluoroacetic acid salt; 
 5-Chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-1H-benzo[d]imidazol-2(3H)-one trifluoroacetic acid salt; 
 6-Chloro-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-1H-benzo[d]imidazol-2(3H)-one trifluoroacetic acid salt; 
 (R)-3,5-Dichloro-7-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (R)-3,5-Dichloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (R)-3,5-Dibromo-7-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (R)-3,5-Dibromo-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (R)-5-Chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-3-methyl-1H-indazole; 
 (R)-5-chloro-2-(cyclopropylmethyl)-7-((1-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-2H-indazole; 
 (R)-5-chloro-2-(cyclopropylmethyl)-7-(1-((4-(4-fluorophenyl)-1methylpiperidin-4-yl)methoxy)ethyl)-2H-indazole; 
 (R)-5-chloro-1-(cyclopropylmethyl)-7-(1-((4-(4-fluorophenyl)-1methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 (R)-2-(5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)ethyl)-2H-indazole-2-yl)acetonitrile; 
 (R)-2-(5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)ethyl)-1H-indazole-2-yl)acetonitrile; 
 (S)-3,5-dichloro-7-(2-fluoro-1-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)ethyl)-1H-indazole; 
 3-(5-chloro-1H-indazol-7-yl)-3-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)propanenitrile; 
 2-(5-chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)piperidine-4-yl)methoxy)-N,N-dimethylethanamine; 
 2-(5-chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)-N,N-dimethylethanamine; 
 5-chloro-7(2,2-difluoro-1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole; 
 5-chloro-7-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)propyl)-1H-indazole; 
 5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)propyl)-1H-indazole; 
 (R)-3,5-dichloro-7-(1-((4-(4-fluorophenyl-1-methyl)piperidine-4-yl)methoxy)ethyl)-2-(2,2,2-trifluoroethyl)-2H-indazole; 
 (R)-3,5-dichloro-7-(1-((4-(4-fluorophenyl-1-methyl)piperidine-4-yl)methoxy)ethyl)-2-(2,2,2-trifluoroethyl)-1H-indazole; 
 (R)-3-bromo-5-chloro-7-(1-((1-methyl-4-phenylpiperidin-4yl)methoxy)ethyl)-1H-indazole; 
 (R)-3,5-dichloro-7-(1-((4-phenylpiperidin-4yl)methoxy)ethyl)-1H-indazole; 
 (R)-3,5-dichloro-7-(1-((1-methyl-4-phenylpiperidin-4yl)methoxy)ethyl)-1H-indazole; 
 (S)-3,5-dichloro-7-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-1h-indazole; 
 (S)-3,5-dichloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1h-indazole; 
 (±)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)indolin-2-one; 
 (±)-5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indole-3-carbonitrile; 
 7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1,3-dimethyl-5-(trifluoromethyl)-1H-indole; 
 (±)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-3-methyl-5-(trifluoromethyl)-1H-indole; 
 (±)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-6-(trifluoromethyl)-1H-indole; 
 (±)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-indole; 
 (±)-4-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)indolin-2-one, TFA; 
 (R)-6-bromo-1-(cyclopropylmethyl)-4-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-benzo[d]imidazole; 
 (S)-6-bromo-1-(cyclopropylmethyl)-4-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-benzo[d]imidazole; 
 (S)-6-bromo-3-(cyclopropylmethyl)-4-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-benzo[d]imidazole; 
 (S)-1-(Cyclopropylmethyl)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; 
 (R)-1-(cyclopropylmethyl)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; 
 (S)-1-(Cyclopropylmethyl)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; 
 (R)-1-(cyclopropylmethyl)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; 
 (S)-1-Ethyl-4-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; and 
 (R)-1-ethyl-4-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
       10. The compound of  claim 1  that is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
       11. The compound of  claim 10  where the salt is the hydrochloride. 
     
     
       12. A composition comprising a pharmaceutically acceptable amount of a compound of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       13. The composition of  claim 12  where the compound is 
       
         
           
           
               
               
           
         
       
     
     
       14. A method for treating a disorder associated with aberrant levels of tachykinins or serotonin comprising administering an effective amount of a compound of  claim 1  to a patient afflicted with the disorder wherein the disorder is anxiety, depression, obsessive compulsive disorder, bulimia, panic disorder, post-traumatic stress disorder, alcohol dependence, or urinary incontinence. 
     
     
       15. The method of  claim 14  where the disorder is anxiety. 
     
     
       16. The method of  claim 14  where the disorder is depression, obsessive compulsive disorder, bulimia, panic disorder, post-traumatic stress disorder, alcohol dependence, or urinary incontinence. 
     
     
       17. The method of  claim 14  where the compound is